The Angeles Clinic and Research Institute 90025 Los Angeles United StatesRekrutierend» Google-MapsDana Farber Cancer Institute 02215 Boston United StatesNoch nicht rekrutierend» Google-MapsCancer and Hematology Centers of Western Michigan-Start Midwest 49546 Grand Rapids United StatesRekrutierend» Google-Maps
Hackensack University Medical Center 07601 Hackensack United StatesRekrutierend» Google-MapsLifespan Cancer Research Institute 02903 Providence United StatesRekrutierend» Google-MapsUniversity of Texas Md Anderson Cancer Center 77030 Houston United StatesRekrutierend» Google-MapsSouth Texas Accelerated Research Therapeutics 78229 San Antonio United StatesRekrutierend» Google-MapsRigshospitalet Uni of Hospital of Copenhagen 02100 Copenhagen DenmarkRekrutierend» Google-MapsHerlev Og Gentofte Hospital 02730 Herlev DenmarkRekrutierend» Google-MapsOdense University Hospital 05000 Odense C DenmarkRekrutierend» Google-MapsVejle Hospital 07100 Vejle DenmarkRekrutierend» Google-MapsCentre Leon Berard 69373 Lyon FranceRekrutierend» Google-MapsInstitut Paoli Calmettes 13009 Marseille FranceNoch nicht rekrutierend» Google-MapsInstitut Gustave Roussy 94805 Villejuif Cedex FranceNoch nicht rekrutierend» Google-MapsFondazione Irccs Istituto Nazionale Del Tumori Di Milano 20133 Milano ItalyRekrutierend» Google-MapsIrccs Istituto Clinico Humanitas 20089 Rozzano ItalyRekrutierend» Google-MapsCentro Ricerche Cliniche Di Verona (Crc) 37134 Verona ItalyRekrutierend» Google-MapsStart Barcelona 08023 Barcelona SpainRekrutierend» Google-MapsHospital General Universitario Vall D Hebron 08035 Barcelona SpainRekrutierend» Google-MapsFundacion Jimenez Diaz University Hospital 28040 Madrid SpainRekrutierend» Google-MapsHospital Universitario 12 de Octubre 28041 Madrid SpainRekrutierend» Google-MapsCentro Integral Oncologico Clara Campal 28050 Madrid SpainRekrutierend» Google-MapsIstituto Oncologico Della Svizzera Italiana 06500 Bellinzona SwitzerlandRekrutierend» Google-MapsCentre Hospitalier Universitaire Vaudois (Chuv) 01011 Lausanne SwitzerlandRekrutierend» Google-MapsKantonsspital St. Gallen 09007 St. Gallen SwitzerlandRekrutierend» Google-MapsCambridge University Hospitals Nhs Foundation Trust CB2 0QQ Cambridge United KingdomRekrutierend» Google-MapsGuys and St Thomas Nhs Foundation Trust SE1 9RT London United KingdomNoch nicht rekrutierend» Google-MapsImperial College Healthcare Nhs Trust - Hammersmith Hospital W12 0HS London United KingdomRekrutierend» Google-MapsThe Christie Nhs Foundation Trust Uk M20 4BV Manchester United KingdomNoch nicht rekrutierend» Google-MapsFreeman Hospital Newcastle Upon Tyne Foundation Nhs Trust NE7 7DN Newcastle Upon Tyne United KingdomRekrutierend» Google-Maps
1. Number of participants with Dose Limiting Toxicities (DLTs) (Time Frame - Up to 28 days)
2. Number of participants with Treatment Emerging Adverse Events (TEAEs) (Time Frame - Up to 2 years)
3. Number of participants with TEAEs leading to dose modification or discontinuation (Time Frame - Up to 2 years)
Secondary outcome:
1. Objective response Rate (Time Frame - 2 years)
2. Disease Control Rate (Time Frame - 2 years)
3. Duration of Response (Time Frame - 2 years)
4. Pharmacokinetics Parameter : Cmax of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
5. Pharmacokinetics Parameter : Tmax of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
6. Pharmacokinetics Parameter : Cmin of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
7. Pharmacokinetics Parameter : AUC(0-t) of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
8. Pharmacokinetics Parameter : AUC 0-∞ of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
9. Pharmacokinetics Parameter : CL/F of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
10. Pharmacokinetics Parameter : Vz/F of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
11. Pharmacokinetics Parameter : t1/2 of INCA33890 (Time Frame - Pre dose - Day 1 of Cycle 1(C1D1)- 28 (each cycle is 28 days), Day 15 of Cycle 1-3; 10min and 4hrs Post dose(PD) - C1D1,C1D4, 24hrs PD C1D2, any time PD Day 4, 8, 22, of Cycle 1, and any time during 30 day Follow Up)
Experimental: Part 1a - Dose Escalation INCA33890 will be administered at a protocol defined starting regimen intravenously. Subsequent dose regimens will be determined during study conduct.
Experimental: Part 1b-Dose Expansion INCA33890 will be administered at the recommended dose(s) for expansion (RDE[s]) in participants with advanced or metastatic ICI sensitive or ICI non sensitive tumor types